USSTOCK.TODAY
Regular Market
Log in Sign up

Kandell Therapeutics shares plunge 38% in after-hours trading on delay of prostate cancer drug application

Stocktwits +1 · ·by G4L

CADL
CADL Candel Therapeutics Inc
$8.39 -9.00%
View chart & analysis →
SF SF -1.04%
  1. 1Kandell Therapeutics expects to submit its Biologics License Application in mid-2027 due to discussions with the FDA.
  2. 2CADL shares fell 38% in Thursday after-hours trading.
  3. 3CADL research and development expenses increased to $15.6 million for the quarter ended September 30.

So what's the key point?

Kandell Therapeutics has pushed back its application for a cancer drug treatment to mid-2027. Following this news, the stock price dropped by 38% in after-hours trading.

Source Stocktwits +1 · View original ↗

Related 3-line summaries

Stifel resumes Buy rating on Starbucks, sets price target at $115 Investing.com +1 · 3d agoStifel Financial achieves record high with $1.46 earnings per share in Q3 The Motley Fool +1 · Oct 226th Annual Palm Beach CorpGov Forum to be Held CorpGov.com · Oct 14
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news